Oxytoine is developed by Rambam Health Care Campus.

What development phase is Oxytoine in?

Oxytoine is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Oxytoine

Rambam Health Care Campus · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Oxytoine
Also known as	syntocinon nasal spray nasal
Sponsor	Rambam Health Care Campus
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Oxytoine CI brief — competitive landscape report
Oxytoine updates RSS · CI watch RSS
Rambam Health Care Campus portfolio CI